Platform Techniques for Preformulation Development for Non-Antibody Products
-
Upload
kbi-biopharma -
Category
Health & Medicine
-
view
162 -
download
0
Transcript of Platform Techniques for Preformulation Development for Non-Antibody Products
![Page 1: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/1.jpg)
Platform Techniques for Preformulation Development for
Non-Antibody Products2009 IBC Non-Antibody Protein Therapeutics
Development and Production
Tim Kelly, Ph.D.Vice President, Biopharmaceutical Development
KBI Biopharma, Inc.
![Page 2: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/2.jpg)
Challenges for Non-Antibody Proteins
• Extraordinarily diverse group of molecules• Enzymes• Interferons• Insulins• Blood Factors• Colony Stimulating Factors• Cytokines• Growth Factors• Conjugates and Fusion Proteins
» Albumins, Enzymes, Antibody fragments• PEGylated and other modified proteins
![Page 3: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/3.jpg)
Challenges for Non-Antibody Proteins
• Diverse process streams & process-related impurity profile
• Host cell proteins: E, coli, yeast, mammalian, insect, plant expression systems
• Unique process steps that impact formulation and analytics» PEGylation, conjugation, etc.
• Diverse and often poorly-understood degradation pathways and product-related impurity profile
• Aggregation, fragmentation, oxidation, deamidation, disulfide exchange, isomerization
» What is critical to maintain potency?
![Page 4: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/4.jpg)
Challenges for Non-Antibody Proteins
• Sizes ranging from a few kDa to >500 kDa• Secondary and Tertiary structure ranging from
relatively unordered to complex, highly ordered, multimeric states
• Glycosylation state ranging from un-glycosylated to complex, highly glycosylated states
• Frequent presence of structurally labile, solvent exposed active sites or effector sites
• Diverse range of functions, activity assays ranging from simple to complex
• Activity assay available and suitable for formulation studies?
![Page 5: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/5.jpg)
Early Development Challenges• Lack of Platform Analytics and Process• Timing of Analytical Development relative to Process
Development and Formulation Development• Chicken vs. Egg• Often do not have suite of orthogonal, stability-indicating
analytical and potency methods to support initial formulation & stability studies
• Typically given very tight timelines to develop a stable Phase I formulation
![Page 6: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/6.jpg)
Use of Biophysical Techniques• Evaluate the suitability of “platform-able” biophysical
techniques to support early formulation studies• Generally able to employ standard analysis
parameters to a broad range of proteins• No extensive method development required
• Characterize the thermal and conformational properties of the protein
• Evaluate the impact of formulation factors on thermal, conformational, and physical stability
• Buffer, pH, excipients, surfactants, protein concentration
![Page 7: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/7.jpg)
Use of Biophysical Techniques• Biophysical Techniques
• Differential Scanning Calorimetry / Microcalorimetry (DSC)» Thermal stability
• Circular Dichroism (CD)» Conformational stability – secondary structure
• Fourier Transform Infrared Spectroscopy (FTIR)» Conformational stability – secondary structure
• Fluorescence Spectroscopy» Conformational stability – tertiary structure
• Dynamic Light Scattering (DLS)» Physical stability
• Scout the various techniques to determine which are most informative for your protein
• Will depend on the unique structural features of the protein
![Page 8: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/8.jpg)
Protein Preformulation Workflow• “Research Phase”
• Biophysical Screening
• Solubility Evaluation
• DOE & Accelerated Stability
• Forced Degradation
Identify critical factors, Eliminate non-critical factors
![Page 9: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/9.jpg)
Preformulation “Research Phase”• Background Information
• pI• MW• Glycosylation state• Secondary & Tertiary Structure• Mechanism of Action, particularly as relates to structure
• Desired Formulation Type• Liquid, Lyophilized Powder, Other
• Route of Administration• IV, SC, IM, etc.
![Page 10: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/10.jpg)
Preformulation “Research Phase”
• Buffer & Formulation pH Selection• Identify suitable buffers based on pKa relative to pI• Solubility considerations• Compatibility with final dosage form
» Buffer type (e.g., lyophilization considerations)• Compatibility with route of administration
» pH and buffer type (e.g., SC injection)
![Page 11: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/11.jpg)
Preformulation “Research Phase”
• Excipient Selection• Polyols and Sugars: Solubility, Thermal Stability, Chemical
Stability• Salt: Solubility, Ionic strength, Osmolality• Amino Acids: Solubility, Viscosity • Surfactants: Aggregates and Particulates• Specific ions or factors required for activity or maintenance of
structure
![Page 12: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/12.jpg)
Initial Biophysical Screening
• To limit the number runs to be evaluated as a part of the DOE study
• Utilize a combination of biophysical tools• DSC: Thermal/conformational stability• DLS: Aggregation and polydispersity• FTIR: Secondary structure evaluation• Circular Dicroism: Secondary structure evaluation• Fluorescence: Conformational stability
• Take advantage of orthogonal techniques to make decisions about formulation factors
![Page 13: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/13.jpg)
CD and FTIR – Structural Analysis
•Overlay spectra from various candidate formulations for comparative evaluation, look for changes to core secondary structural elements
•CD more sensitive for α–helix, FTIR more sensitive for β-sheet
•Not Quantitative
-0.004
-0.003
-0.002
-0.001
0
0.001
0.002
160016201640166016801700
Wavenumber (cm-1)
AU
α-helix β-sheet
CD FTIR
![Page 14: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/14.jpg)
CD method conditions; Structural analysis
• Buffer subtraction• Normalization (using protein concentration)• May be used to estimate secondary structural contents
Data analysis
Five (averaged)Scans/sample
100nm/minScan speed
1nmData Pitch
1 secResponse
1nmBandwidth
Jasco J-810 CD SpectrapolarimeterInstrument
100mdegSensitivity
50µLVolume requirement
0.1mm (quartz cuvette)Pathlength
190-250nm (far UV region)250-350nm (near UV region)
Scan range
2mg/mL (may be changed to obtain sufficient signal-to-noise ratio)Sample concentration
![Page 15: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/15.jpg)
CD method conditions; T-melt analysis
20ºCStart temperature
100ºCFinal temperature
• Buffer subtraction (if available)• First derivative analysis to obtain Tm value
Data analysis
1ºC/minTemperature slope
1nmData Pitch
1 secResponse
1nmBandwidth
Jasco J-810 CD SpectrapolarimeterInstrument
100mdegSensitivity
300µLVolume requirement
1mm (quartz cuvette)Pathlength
Selected based on protein’s secondary structural content (suggested values: 222nm for proteins with predominant α-helical structure, 218nm for proteins with predominant β-sheet structure)Monitor Wavelength
2mg/mL (may be changed to obtain sufficient signal-to-noise ratio)Sample concentration
![Page 16: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/16.jpg)
FTIR method conditions
• 100µL for ATR stage• 10µL for Bio-Cell
Volume
400 (acquisition time ~20 minutes)Scans/sample
Single BeamData Type
ABB FTLA2000 FTIR (using either SensIR ATR stage or Bio-Cell)Instrument
• Background subtraction• Buffer subtraction• Vapor subtraction• Normalization• Second derivative
Data Analysis
ZeroInitial delay
4cm-1Resolution
4000-500 cm-1Scan range
10mg/mL (may be changed to obtain sufficient signal-to-noise ratio)Sample concentration
![Page 17: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/17.jpg)
Use of CD Thermal Analysis for Buffer/pH Selection
-1
3
0
1
2
CD[mdeg]
400
415
405
410
25 7530 40 50 60 70
HT[V]
Temperature [C]
-0.4
1
0
0.5
CD[mdeg]
382
390
384
386
388
25 8040 60
HT[V]
Temperature [C]
Enzyme in Acetate, Sucrose, pH 4.0 Enzyme in Tris, Sucrose, pH 8.0
Tm: 39.5oC Tm: 52.5oC
Difference of 13°C!
![Page 18: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/18.jpg)
Structural Content by CD and FTIR
-8E+006
4E+006
-5E+006
0
200 250210 220 230 240
Mol. Ellip.
Wavelength [nm]
-8E+006
4E+006
-5E+006
0
200 250210 220 230 240
Mol. Ellip.
Wavelength [nm]
- Formulation 1
- Formulation 2
- Formulation 3
45%
45%
45%
α-helix
FTIR
35%
37%
38%
α-helix
CDβ-sheet
14%Formulation 3
13%Formulation 2
12%Formulation 1
-Lot 1
-Lot 2
-Lot 3
Amide I
Amide II
![Page 19: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/19.jpg)
DSC method conditions
400 µL of 2mg/mL in formulation buffer (may be changed to obtain acceptable signal-to-noise ratio)Sample requirements
35ºCFill temperature
MicroCal, VP-DSC Capillary Cell MicrocalorimeterInstrument
• Buffer subtraction and normalization (using protein conc.)• Determine Tm values (mid-point of major peaks)Data analysis
NoneFeedback mode/gain
16 secFiltering period
25ºCPost-cycle thermostat
0 minPost-scan thermostat
10 minPre-scan thermostat
60ºC/hrScan rate
110ºCFinal temperature
20ºCStart temperature
![Page 20: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/20.jpg)
Comparison of DSC and CD for Thermal Analysis
-1
4
0123
CD[mdeg]
360
374
365
370
30 8040 50 60 70
HT[V]
Temperature [C]
40 50 60 70
0
20
40
60
80
100 Data: m072606002dsc_cpModel: MN2StateChi^2/DoF = 1.674E6Tm 52.33 ±0.011∆H 4.112E5 ±2.22E3∆Hv 1.828E5 ±1.23E3
m072606002dsc_cp M072606002DSC_CPPEAK1
Cp
(kca
l/mol
e/o C
)
Temperature (oC)
Tm = 52°COnset of unfolding = 43°C
Tm = 52°COnset of unfolding = 46°C
Enzyme A
![Page 21: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/21.jpg)
Comparison of DSC and CD for Thermal Analysis
40 50 60 70
0
50
100
150
Data: m072606003dsc_cpModel: MN2StateChi^2/DoF = 6.379E6Tm1 55.37 ±0.015∆H1 4.868E5 ±7.21E3∆Hv1 2.686E5 3.17E3Tm2 59.83 ±0.13∆H2 1.350E5 ±8.19E3∆Hv2 1.733E5 1.27E4 m072606003dsc_cp
M072606003DSC_CPFIT M072606003DSC_CPPEAK1 M072606003DSC_CPPEAK2
Cp
(kca
l/mol
e/o C
)
Temperature (oC)
-1
4
0123
CD[mdeg]
370
400
380
390
30 8040 50 60 70
HT[V]
Temperature [C]
Tm = 55°COnset of unfolding = 49°C
Tm1 = 55°COnset of unfolding = 47°CTm2 = 60°C
Enzyme B
![Page 22: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/22.jpg)
Effects of pH for Glycoprotein A
20 40 60 80 100 120-0.00015
-0.00010
-0.00005
0.00000
20mM Glutamate, pH 4.0, Tm 53.2°C 20mM Glutamate, pH 4.5, Tm 57.3°C
Cp(
cal/o C
)
Temperature (oC)
![Page 23: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/23.jpg)
Effects of pH for Glycoprotein A
20 40 60 80 100 120-0.00015
-0.00010
-0.00005
0.00000
0.00005 20mM Acetate, pH 4.5; Tm 57.1°C 20mM Acetate, pH 5.5; Tm 59.4°C
Cp(
cal/o C
)
Temperature (oC)
20 40 60 80 100 120-0.00015
-0.00010
-0.00005
0.00000
0.00005
20mM Histidine, pH 5.5, Tm 58.5°C 20mM Histidine, pH 6.5, Tm 60.1°C
Cp(
cal/o C
)
Temperature (oC)
![Page 24: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/24.jpg)
Effects of buffer type for Glycoprotein A
20 40 60 80 100 120-0.00015
-0.00010
-0.00005
0.00000 20mM Glutamate, pH 4, Tm 53.2°C 20mM Succinate, pH 4, Tm 54.5°C 20mM Lactate, pH 4, Tm 53.3°C 20mM Glycolate, pH 4, Tm 53.8°C
Cp(
cal/o C
)
Temperature (oC)
20 40 60 80 100 120-0.00015
-0.00010
-0.00005
0.00000
0.00005
20mM Phosphate, pH 5.5, Tm 61.5°C 20mM Histidine, pH 5.5, Tm 60.1°C
Cp(
cal/o C
)
Temperature (oC)
![Page 25: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/25.jpg)
DSC can be used to compare different lots
20 30 40 50 60 70 80 90 100 110 120-30
-25
-20
-15
-10
-5
0
5
10
Lot A, Replicate 1 Lot B, Replicate 2 Lot C, Replicate 3
Cp
(kca
l/mol
e/o C
)
Temperature (oC)
20 30 40 50 60 70 80 90 100 110 120-30
-25
-20
-15
-10
-5
0
5
Lot A, Replicate 2 Lot B, Replicate 2 Lot C, Replicate 2
Cp
(kca
l/mol
e/o C
)
Temperature (oC)
•Very similar Tm values obtained for the three lots20 30 40 50 60 70 80 90 100 110 120
-35
-30
-25
-20
-15
-10
-5
0
5
Lot A, Replicate 3 Lot B, Replicate 3 Lot C, Replicate 3
Cp
(kca
l/mol
e/o C
)
Temperature (oC)
S ample L ot T m Av g . T m S td. Dev . % R S D
L ot A, R ep 1 67.3L ot A, R ep 2 67.0L ot A, R ep 3 66.9L ot B , R ep 1 66.6L ot B , R ep 2 66.6L ot B , R ep 3 66.7L ot C , R ep 1 67.8L ot C , R ep 2 67.6L ot C , R ep 3 67.7
Av e rag e 67.1S td. Dev . 0.5%R S D 0.8
67.7
% R S D = 100*( S td. Dev. /Avg)
0.2
0.0
0.1
67.1
66.6
0.3
0.1
0.2
![Page 26: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/26.jpg)
DLS method conditions
Sarstedt, Cat. No. 67.754 (disposable; volume requirement: 1mL)Cuvette
Automatic (selected by the instrument to optimize signal-to-noise)Attenuation
173º (backscatter)Measurement Angle
1.450 (typical for protein samples)1.330 (for water as the dispersant)Refractive Index
Malvern Zetasizer Nano-ZS, Model 3600Instrument
• Based on general purpose method (normal resolution)• Compare Z-average diameter, PDI values for overall cumulant analysis• Compare width and hydrodynamic diameter for all peaks in the intensity distribution profiles• Not recommended to be used for quantifying the relative amounts of various size species in a
sample
Data Analysis
0.8872cP (for water under these conditions)Viscosity
25°CTemperature
Five measurements averaged, each with 10-15 runsMeasurements
2mg/mL in formulation bufferSample concentration
![Page 27: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/27.jpg)
Effect of Buffer Type for Glycoprotein A
0
5
10
15
20
0.1 1 10 100 1000 10000
Inte
nsity
(%)
Size (d.nm)
Size Distribution by Intensity
Record 118: 20mM phosphate, pH 6.5 Record 119: 20mM histidine, pH 6.5
![Page 28: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/28.jpg)
Effect of pH for Glycoprotein B
0
5
10
15
20
0.1 1 10 100 1000 10000
Inte
nsity
(%)
Size (d.nm)
Size Distribution by Intensity
Record 123: 20mM succinate, pH 4.0 Record 124: 20mM succinate, pH 4.5
![Page 29: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/29.jpg)
Effect of Buffer Type and pH for Glycoprotein B
0
5
10
15
20
0.1 1 10 100 1000 10000
Inte
nsity
(%)
Size (d.nm)
Size Distribution by Intensity
Record 125: 20mM acetate, pH 4.5 Record 126: 20mM lactate, pH 4.0Record 127: 20mM lactate, pH 4.5
![Page 30: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/30.jpg)
Summary of DSC and DLS Screening for Glycoprotein A
Tm versus buffer type at various pH conditions
48
50
52
54
56
58
60
62
64
Glutam
ateSucc
inateLac
tic A
cid
Glycolic
Acid
Glutam
ateSucc
inateLac
tic A
cid
Glycolic
Acid
Acetat
e Citr
ate
Acetat
e Hist
idinePhosp
hate
Histidine
Citrate
Phospha
te Tris
Buffer type
Tm (d
eg C
)
Tm
pH 4.0
pH 4.5 pH 5.5pH 6.5 pH 7.0 pH 8.0
PDI versus buffer type at various pH conditions
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Glutam
ateSucc
inateLac
tic A
cidGlyc
olic A
cidGlut
amate
Succinate
Lactic
Acid
Glycolic
Acid
Acetat
e Citr
ate
Acetat
e Hist
idinePhosp
hate
Histidine
Citrate
Phospha
te Tris
Buffer type
PDI
pH 4.0 pH 4.5 pH 5.5pH 6.5 pH 7.0 pH 8.0
• DSC indicates thermal stability is a function of pH• DLS reveals differences in physical stability as a function of buffer type and pH• Chose to further evaluate Acetate, Histidine and Glycolate
![Page 31: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/31.jpg)
Fluorescence Spectroscopy using ANS• 1,8-ANS - Amphiphilic probe that exhibits negligible
fluorescence in water yet reveals a significant increase in fluorescent intensity when bound to hydrophobic regions on a protein
• As a protein unfolds, hydrophobic core regions that are inaccessible to the dye in the native structure are exposed and bound by the dye thereby increasing the fluorescent intensity of the sample.
![Page 32: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/32.jpg)
Fluorescence Spectroscopy using ANS
Effect of Buffer, pH and Sucrose Concentration after 11 Days at 40°C/75%RH
0
50000
100000
150000
200000
250000
300000
400 500 600 700
Wavelength (nm)
Inte
nsity
(cps
)
Tris High Sucrose pH 8
Tris Low Sucrose pH 8
HEPES High Sucrose pH 7.5
HEPES Low Sucrose pH 7.5
![Page 33: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/33.jpg)
Fluorescence Spectroscopy using ANS
![Page 34: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/34.jpg)
Potentially “Platform-able” Analytical Techniques
• cIEF – Imaged CE• SDS-CGE and Microchip electrophoresis
• Take advantage of manufacturer’s kit chemistry to rapidly develop preliminary methods
• SEC-HPLC• SDS-PAGE• HIAC (non-USP, low volume syringes)
• Surfactant evaluation studies» Agitation and Freeze-thaw in the absence of surfactant and at
different surfactant levels» Use in combination with DLS, SDS-PAGE, SEC
![Page 35: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/35.jpg)
Conclusions• Biophysical techniques may be applied to a broad range of
protein therapeutics using standard analysis parameters• Use to rapidly evaluate the impact of primary formulation factors
on thermal, conformational, and physical stability • Identify a smaller subset of conditions which appear to be optimal• Characterize a preliminary design space within which the native
three dimensional conformation of the protein is maintained• May constitute part of a “platform approach” for initial
preformulation studies, greatly increasing our knowledge about the protein while stability-indicating analytical methods are still under development
![Page 36: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/36.jpg)
Acknowledgements• Pooja Arora, PhD, Group Leader, Biopharmaceutical Development
• Juan Davagnino, PhD, Associate Director, Biopharmaceutical Development
• Vickie Dowling, PhD, Group Leader, Biopharmaceutical Development
• Wayne Yount, PhD, Group Leader, Biopharmaceutical Development
• Steven Cottle, MS, Scientist I, Biopharmaceutical Development
![Page 37: Platform Techniques for Preformulation Development for Non-Antibody Products](https://reader031.fdocuments.net/reader031/viewer/2022022123/58a62df51a28ab416c8b6563/html5/thumbnails/37.jpg)
Thank You!